{
  "model": "claude-opus-4-5-20251101",
  "prompt_version": "v2",
  "prompt_name": "Structured with examples",
  "timestamp": "2026-01-19T20:52:01.979339",
  "per_article_results": [
    {
      "pmcid": "PMC5508045",
      "variants": [
        {
          "variant": "rs9923231",
          "generated": "Genotypes GA and AA of VKORC1 -1639G>A (rs9923231) are associated with decreased dose of warfarin in Thai patients as compared to genotype GG.",
          "ground_truth": [
            "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC."
          ],
          "best_similarity": 0.34210526315789475,
          "best_match_idx": 0,
          "best_match": "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.",
          "all_similarities": [
            0.34210526315789475
          ]
        },
        {
          "variant": "rs1057910",
          "generated": "CYP2C9 *1/*3 is associated with decreased dose of warfarin in Thai patients as compared to CYP2C9 *1/*1.",
          "ground_truth": [
            "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA."
          ],
          "best_similarity": 0.2857142857142857,
          "best_match_idx": 0,
          "best_match": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.",
          "all_similarities": [
            0.2857142857142857
          ]
        },
        {
          "variant": "rs2108622",
          "generated": "Genotype TT is associated with increased dose of warfarin in Thai patients as compared to genotype CC.",
          "ground_truth": [
            "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC."
          ],
          "best_similarity": 0.5,
          "best_match_idx": 0,
          "best_match": "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.",
          "all_similarities": [
            0.5
          ]
        },
        {
          "variant": "rs887829",
          "generated": "UGT1A1 rs887829 is not associated with dose of warfarin in Thai patients.",
          "ground_truth": [
            "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T."
          ],
          "best_similarity": 0.26666666666666666,
          "best_match_idx": 0,
          "best_match": "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.",
          "all_similarities": [
            0.26666666666666666
          ]
        }
      ],
      "avg_similarity": 0.3486215538847118
    },
    {
      "pmcid": "PMC554812",
      "variants": [
        {
          "variant": "HLA-B*58:01",
          "generated": "HLA-B*58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in Han Chinese people with hyperuricemia.",
          "ground_truth": [
            "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.6190476190476191,
          "best_match_idx": 0,
          "best_match": "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.6190476190476191
          ]
        },
        {
          "variant": "HLA-DRB1*03:01",
          "generated": "HLA-DRB1*0301 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in Han Chinese people with hyperuricemia as compared to non-carriers.",
          "ground_truth": [
            "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.52,
          "best_match_idx": 0,
          "best_match": "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.52
          ]
        },
        {
          "variant": "HLA-C*03:02",
          "generated": "HLA-B*58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in Han Chinese people with hyperuricemia as compared to non-carriers.",
          "ground_truth": [
            "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.52,
          "best_match_idx": 0,
          "best_match": "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.52
          ]
        },
        {
          "variant": "HLA-A*33:03",
          "generated": "HLA-A*33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in Han Chinese people with hyperuricemia as compared to non-carriers.",
          "ground_truth": [
            "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.52,
          "best_match_idx": 0,
          "best_match": "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.52
          ]
        },
        {
          "variant": "rs1594",
          "generated": "HLA-B*5801 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in Han Chinese.",
          "ground_truth": [
            "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G."
          ],
          "best_similarity": 0.43478260869565216,
          "best_match_idx": 0,
          "best_match": "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.",
          "all_similarities": [
            0.43478260869565216
          ]
        }
      ],
      "avg_similarity": 0.5227660455486542
    }
  ],
  "avg_similarity": 0.4453684936980131,
  "total_variants": 9
}